TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination.

In COVID-19 clinical update #49, Daniel Griffin discusses CDC guidelines on mask use, drop in test frequency in the US, resurgence of COVID-19 in Brazil, possible impact of Pfizer vaccine on viral load, EUA for bamlanivimab and etesevimab administered together, and preliminary results of Tocilizumab in hospitalized patients.